secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013481
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix reports Q2 net income of $19.3M on Elfabrio sales and $20M milestone
-----------------------------------------------------------------------------

- Revenue from goods $15.1M (+344% YoY) driven by Elfabrio sales to Chiesi after FDA/EMA approvals.
- License & R&D revenue $20.0M (+270% YoY) from $20M regulatory milestone payment from Chiesi.
- Net income $19.3M ($0.29 basic EPS) vs net loss of $5.3M in Q2 2022; cash $48.2M.
- Elfabrio received US FDA (May 10) and EU (May 5) approval for adult Fabry disease; launched in US by Chiesi.
- PRX-115 phase I trial for severe gout ongoing; 16 patients dosed to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/0001558370-23-013481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023013481/plx-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer